According to the Xinhua Pharmaceutical announcement, the company has received the “Drug Registration Certificate” for the concentrated solution of magnesium, sodium, and potassium sulfate approved and issued by the State Drug Administration. The drug is a class 4 chemical prescription drug, suitable for intestinal cleansing before adult intestinal cleansing operations. It is a Class B variety of the 2025 edition of the National Medical Insurance. In 2025, Chinese public medical institutions will have sales of about 490 million yuan of this drug. This certification will enrich the company's digestive system drug product line. There is uncertainty about drug sales, so investors are invited to be aware of the risks.

According to the Xinhua Pharmaceutical announcement, the company has received the “Drug Registration Certificate” for the concentrated solution of magnesium, sodium, and potassium sulfate approved and issued by the State Drug Administration. The drug is a class 4 chemical prescription drug, suitable for intestinal cleansing before adult intestinal cleansing operations. It is a Class B variety of the 2025 National Medical Insurance. In 2025, Chinese public medical institutions will have sales of about 490 million yuan of this drug. This certification will enrich the company's digestive system drug product line. There is uncertainty about drug sales, so investors are invited to be aware of the risks.